Nuclear Medicine and Biology
Volume 33, Issue 6 , Pages 751-764 , August 2006

Alkyl-fluorinated thymidine derivatives for imaging cell proliferation: I. The in vitro evaluation of some alkyl-fluorinated thymidine derivatives

  • Jun Toyohara

      Affiliations

    • Probe Research Section, Department of Molecular Probe, Molecular Imaging Center, National Institute of Radiological Sciences, Chiba 263-8555, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 43 206 4041; fax: +81 43 206 3261.
    • ,
  • Akio Hayashi

      Affiliations

    • Research and Development Division, Research Center, Nihon Medi-Physics Co., Ltd., Chiba 299-0266, Japan
    • ,
  • Akie Gogami

      Affiliations

    • Research and Development Division, Research Center, Nihon Medi-Physics Co., Ltd., Chiba 299-0266, Japan
    • ,
  • Masahiro Hamada

      Affiliations

    • Department of Pharmaceutical Manufacturing Chemistry, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan
    • ,
  • Yoshio Hamashima

      Affiliations

    • Department of Pharmaceutical Manufacturing Chemistry, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan
    • ,
  • Takahiro Katoh

      Affiliations

    • Department of Pharmaceutical Manufacturing Chemistry, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan
    • ,
  • Manabu Node

      Affiliations

    • Department of Pharmaceutical Manufacturing Chemistry, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan
    • ,
  • Yasuhisa Fujibayashi

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Fukui 910-1193, Japan

Received 16 January 2006 ,Revised 16 June 2006 ,Accepted 19 June 2006.

References 

  1. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972–1980
  2. Yamada Y, Uchida Y, Tatsumi K, Yamaguchi T, Kimura H, Kitahara H, et al. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med. 1998;39:1160–1166
  3. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409–1415
  4. Shreve PD, Anzai Y, Whal RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics. 1999;19:61–77
  5. Thorgeirsson SS, Okayama H. The United States–Japan cooperative cancer research program seminar on “Cell cycle control and cancer”. Jpn J Cancer Res. 1998;89:1093–1097
  6. Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, et al. 2-[C-11]Thymidine imaging of malignant brain tumors. Cancer Res. 1999;59:615–621
  7. Martiat P, Ferrant A, Labar D, Cogneau A, Boc C, Michel JL, et al. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med. 1998;29:1633–1637
  8. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757–1762
  9. Vander Broght T, Pauwels S, Lambotte L, Labar D, De Maeght S, Stroobandt G, et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med. 1994;35:974–982
  10. Van Eijkeren ME, De Schryver A, Goethals P, Poupeye E, Schelstraete K, Lemahieu I, et al. Measurement of short term 11C-thymidine activity in human head and neck tumours using positron emission tomography (PET). Acta Oncol. 1992;31:539–543
  11. Blasberg RG, Roelcke U, Weinreich R, Beattie B, Ammon K, Yonekawa Y, et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res. 2000;60:624–635
  12. Tjuvajev J, Muraki A, Ginos J, Berk J, Koutcher D, Ballon B, et al. Iododeoxyuridine (IUDR) uptake and retention as a measure of tumor growth. J Nucl Med. 1993;34:1152–1161
  13. Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, et al. Imaging of the brain tumor proliferative activity with [131I]iododeoxyuridine. J Nucl Med. 1994;35:1407–1417
  14. Wakanabe KA, Reichman U, Hirota K, Lopez C, Fox JJ. Nucleosides 110. Synthesis and antiherpes virus activity of some 2′-fluoro-2′-deoxyarabinofuranosylpyrimidine nucleosides. J Med Chem. 1979;22:21–24
  15. Alauddin MM, Conti PS, Fissekis JD. Synthesis of [18F]-labeled 2′-deoxy-2′-fluoro-5-methyl-1-β-d-arabinofuranosyluracil ([18F]-FMAU). J Label Compd Radiopharm. 2002;45:583–590
  16. Conti PS, Alauddin MM, Fissekis JR, Schmall B, Watanabe KA. Synthesis of 2′-fluoro-5-[11C]-methyl-1-β-d-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol. 1995;22:783–789
  17. Mangner TJ, Klecker RW, Anderson L, Shields AF. Synthesis of 2′-deoxy-2′-[18F]fluoro-β-d-arabinofuranosyl nucleosides, [18F]FAU, [18F]FMAU, [18F]FBAU and [18F]FIAU, as potential PET agents for imaging cellular proliferation. Synthesis of [18F]labelled FAU. FMAU, FBAU, FIAU. Nucl Med Biol. 2003;30:215–224
  18. Sun H, Solan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005;32:15–22
  19. Grant AJ, Feinberg A, Chou TC, Watanabe KA, Fox JJ, Philips FS. Incorporation of metabolites of 2′-fluoro-5-iodo-1-β-d-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochem Pharmacol. 1982;31:1103–1108
  20. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–1336
  21. Cheng YC, Dutschman G, Fox JJ, Watanabe KA, Machida H. Differential activity of potential antiviral nucleoside analogs on herpes simplex virus-induced and human cellular thymidine kinases. Antimicrob Agents Chemother. 1981;20:420–423
  22. Wang J, Eriksson S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-β-d-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob Agents Chemother. 1996;40:1555–1557
  23. Toyohara J, Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281–287
  24. Grierson JR, Shields AF. Radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 2000;27:143–156
  25. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol. 2004;31:829–837
  26. Ditmann H, Dohman BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462–1469
  27. Rahim SG, Trivedi N, Bogunovic-Batchelor MV, Hardy GW, Mills G, Selway JW, et al. Synthesis and anti-herpes virus activity of 2′-deoxy-4′-thiopyrimidine nucleosides. J Med Chem. 1996;39:789–795
  28. Toyohara J, Hayashi A, Sato M, Tanaka H, Haraguchi K, Yoshimura Y, et al. Rationale of 5-125I-4′-thio-2′-deoxyuridine as a potential iodinated proliferation marker. J Nucl Med. 2002;43:1218–1226
  29. Toyohara J, Gogami A, Hayashi A, Yonekura Y, Fujibayashi Y. Pharmacokinetics and metabolism of 5-125I-4′-thio-2′-deoxyuridine in rodents. J Nucl Med. 2003;44:1671–1676
  30. Griengl H, Wanek E, Schwarz W, Steicher W, Rosenwirth B, Clercq ED. 2′-Fluorinated arabinonucleosides of 5-(2-haloalkyl)uracil: synthesis and antiviral activity. J Med Chem. 1987;30:1199–1204
  31. R. Walker, P. Coe, S.G. Rahim, Further antiviral pyrimidine nucleosides. International Publication WO9104982.
  32. Ogilvie KK, Beaucage SL, Gillen MF, Entwistle D, Quilliam M. Fluoride ion catalyzed alkylation of purines, pyrimidines, nucleosides and nucleotides using alkyl halides. Nucleic Acid Res. 1979;6:1695–1708
  33. Balzarini J, Celen S, Karlsson A, de Groot T, Verbruggen A, Bormans G. The effect of a methyl or 2-fluoroethyl substituent at the N-3 position of thymidine, 3′-fluoro-3′-deoxythymidine and 1-β-d-arabinosylthymine on their antiviral and cytostatic activity in cell culture. Antivir Chem Chemother. 2006;17:17–23
  34. Otter GP, Elzagheid MI, Johens GD, MacCulloch AC, Walker RT, Oivanen M, et al. Synthesis and hydrolytic stability of the α and β anomers of 4′-thio-2′-deoxyuridine and their 5-substituted analogs. Competition between the acid-catalysed depyrimidination and isomerisation to 5-thiopyranoside nucleoside. J Chem Soc Perkin Trans. 1998;2:2343–2349
  35. Lunato AJ, Wang J, Woollard JE, Anisuzzaman AKM, Ji W, Rong FG, et al. Synthesis of 5-(carboranylalkylmercapto)-2′-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. J Med Chem. 1999;42:3378–3389
  36. Chi DY, Kilbour MR, Katzenellenbogen JA, Brodack JW, Welch MJ. Synthesis of no-carrier-added N-([18F]fluoroalkyl)spiperone derivatives. Appl Radiat Isot. 1986;37:1173–1180
  37. Sasaki T, Minamoto K, Suzuki H. Elimination reaction on the di- and trimesylated derivatives of N3-benzyluridine. J Org Chem. 1973;38:598–607
  38. Yamamoto I, Kimura T, Tateoka Y, Watanabe K, Ho IK. N-substituted oxopyrimidines and nucleosides: structure–activity relationship for hypnotic activity as central nervous system depressant. J Med Chem. 1987;30:2227–2231
  39. Fissekis JD, Myles A, Brown GB. Synthesis of 5-hydroxyalkylpyrimidines from lactones. J Org Chem. 1964;29:2670–2673
  40. Dyson MR, Coe PL, Walker RT. An improved synthesis of benzyl 3,5-di-O-benzyl-2-deoxy-1,4-dithio-d-erythro-pentofuranoside, an intermediate in the synthesis of 4′-thionucleosides. Carbohydr Res. 1991;216:237–248
  41. Edgell WF, Parts L. Synthesis of alkyl and substituted alkyl fluorides from p-toluenesulfonic acid esters. The preparation of p-toluenesulfonic acid esters of lower alcohols. J Am Chem Soc. 1955;77:4899–4902
  42. Wilds CJ, Damha MJ. 2′-Deoxy-2′-fluoro-β-d-arabinonucleosides and oligonucleotides (2′F-ANA): synthesis and physicochemical studies. Nucleic Acids Res. 2000;28:3625–3635
  43. Bradshaw MD, Deininger PL. Human thymidine kinase gene: molecular cloning and nucleotide sequence of a cDNA expressible in mammalian cells. Mol Cell Biol. 1984;11:2316–2320
  44. Gati P, Misra HK, Knaus EE, Wiebe LI. Structural modifications at the 2′- and 3′-positions of some pyrimidine nucleosides as determinations of their interaction with the mouse erythrocyte nucleoside transporter. Biochem Pharmacol. 1984;33:3325–3331
  45. Gati WP, Knaus EE, Wiebe LI. Interaction of 2′-halogeno-2′-deoxyuridines with the human erythrocyte nucleoside transport mechanism. Mol Pharmacol. 1983;23:146–152
  46. Komatsu T, Yamazaki H, Shimada N, Nagayama S, Kawaguchi Y, Nakajima M, et al. Involvement of microsomal cytochrome p450 and cytosolic thymidine phosphorylase in 5-fluorouracil formation from tegaful in human liver. Cancer Res. 2001;7:675–681
  47. Al-Madhoun AS, Johnsamuel J, Barth RF, Tjarks W, Eriksson S. Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res. 2004;64:6280–6286
  48. Byun Y, Yan J, Al-Madhoun AS, Johnsamuel J, Yang W, Barth RF, et al. Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy. J Med Chem. 2005;48:1188–1198
  49. Hanes CS. Studies of plant amylases: I. The effect of starch concentration upon the velocity of hydrolysis by the amylase of germinated barley. Biochem J. 1932;26:1406–1421
  50. Dixon M. The determination of enzyme inhibitor constants. Biochem J. 1953;55:170–171
  51. Dixon M, Webb EC. Inhibitors. In:  Dixon EC,  Webb DC editor. Enzymes. 3rd ed.. London: Longman; 1979;p. 332–380
  52. Eisenthal R, Cornish-Bowden A. The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters. Biochem J. 1974;139:715–720
  53. Johansson NG, Eriksson S. Structure–activity relationships for phosphorylation of nucleoside analogs to monophosphates by nucleoside kinases. Acta Biochim Pol. 1996;43:143–160
  54. Eriksson S, Kierdaszuk B, Munch-Petersen B, Öberg B, Johansson NG. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun. 1991;176:586–592
  55. Al-Madhoun AS, Tjarks W, Eriksson S. The role of thymidine kinases in the activation of pyrimidine nucleoside analogs. Mini Rev Med Chem. 2004;4:341–350
  56. Al-Madhoun AS, Johansamuel J, Yan J, Ji W, Wang J, Zhou JC, et al. Synthesis of a small library of 3-(carboranylalkyl)thymidines and their biological evaluation as substrates for human thymidine kinase 1 and 2. J Med Chem. 2002;45:4018–4028
  57. Tjarks W, Wang J, Chandra S, Ji W, Zhuo J, Lunato AJ, et al. Synthesis and biological evaluation of boronated nucleosides for boron neutron capture therapy (BNCT) of cancer. Nucleosides Nucleotides Nucleic Acids. 2001;20:695–698
  58. Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab. 2004;5:63–84
  59. Paterson ARP, Cass CE. Transport of nucleoside drugs in animal cells. In:  Goldman ID editors. Membrane transport of antineoplastic agents. New York: Pergamon Press; 1986;p. 309–329
  60. Plagemann PGW, Wohlhueter RM. Permeation of nucleosides, nucleic acid bases, and nucleotides in animal cells. Curr Top Membr Transp. 1980;14:225–330
  61. Jarvi SM. Adenosine transporters. In:  Cooper DMF,  Londons C editor. Adenosine receptors. New York: Alan R. Liss, Inc.; 1988;p. 113–123
  62. Belt JA. Heterogeneity of nucleoside transport in mammalian cells. Two types of transport activity in L1210 and other cultured neoplastic cells. Mol Pharmacol. 1983;24:479–484
  63. Plagemann PGW, Wohlhueter RM. Nucleoside transport in cultured mammalian cells. Multiple forms with different sensitivity to inhibition by nitrobenzylthioinosine or hypoxantine. Biochem Biophys Acta. 1984;773:39–52
  64. Belt JA, Noel LD. Nucleoside transport in walker 256 rat carcinosarcoma and S49 mouse lymphoma cells. Biochem J. 1985;232:681–688
  65. Jarvis SM, Young JD. Nucleoside transport in rat erythrocytes: two components with differences in sensitivity to inhibition by nitrobenzylthioinosine and p-chloromercuryphenyl sulfonate. J Membr Biol. 1986;93:1–10
  66. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochem Biophys Acta. 1996;1286:153–181
  67. Belt JA, Marina NM, Phelps DA, Crawford CR. Nucleoside transport in normal and neoplastic cells. Adv Enzyme Regul. 1993;33:235–252
  68. Kornberg A, Baker TA. Biosynthesis of DNA precursors. In:  Kornberg A,  Baker TA editor. DNA replication. 2nd ed.:New York: Freeman; 1992;p. 53–100

PII: S0969-8051(06)00104-1

doi: 10.1016/j.nucmedbio.2006.06.003

Nuclear Medicine and Biology
Volume 33, Issue 6 , Pages 751-764 , August 2006

Article Tools

* Image Usage & Resolution